Total Payments
$568,170
2024 Payments
$136,697
Companies
34
Transactions
318
Medicare Patients
138
Medicare Billing
$11,778
Payment Breakdown by Category
Consulting$304,841 (53.7%)
Other$182,871 (32.2%)
Travel$63,262 (11.1%)
Food & Beverage$8,691 (1.5%)
Research$7,927 (1.4%)
Gifts$353.47 (0.1%)
Education$225.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $304,841 | 97 | 53.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,160 | 27 | 15.3% |
| Current or prospective ownership or investment interest | $79,231 | 3 | 13.9% |
| Travel and Lodging | $63,262 | 64 | 11.1% |
| Food and Beverage | $8,691 | 111 | 1.5% |
| Honoraria | $8,580 | 2 | 1.5% |
| Unspecified | $7,927 | 7 | 1.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,800 | 1 | 0.8% |
| Grant | $2,500 | 1 | 0.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $600.00 | 1 | 0.1% |
| Gift | $353.47 | 2 | 0.1% |
| Education | $225.26 | 2 | 0.0% |
Payments by Type
General
$560,243
311 transactions
Research
$7,927
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $112,941 | 24 | $0 (2024) |
| Boston Scientific Corporation | $82,526 | 8 | $0 (2022) |
| Abbott Laboratories | $66,647 | 28 | $0 (2022) |
| Daiichi Sankyo Company LTD | $50,705 | 27 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $40,706 | 25 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $39,105 | 20 | $0 (2024) |
| Medtronic, Inc. | $34,477 | 49 | $0 (2024) |
| CSL Behring | $34,453 | 22 | $0 (2024) |
| Janssen Research & Development, LLC | $22,626 | 17 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $20,307 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $136,697 | 80 | Novo Nordisk AS ($77,799) |
| 2023 | $112,312 | 63 | Novo Nordisk AS ($31,392) |
| 2022 | $14,340 | 31 | Medtronic, Inc. ($4,708) |
| 2021 | $7,444 | 4 | Novartis Pharmaceuticals Corporation ($5,940) |
| 2020 | $3,225 | 5 | Daiichi Sankyo Inc. ($2,415) |
| 2019 | $42,944 | 25 | Daiichi Sankyo Inc. ($13,292) |
| 2018 | $185,907 | 53 | Boston Scientific Corporation ($74,309) |
| 2017 | $65,301 | 57 | Abbott Laboratories ($19,897) |
All Payment Transactions
318 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | CORDIS US CORP. | Cardio (Device) | Consulting Fee | Cash or cash equivalent | $6,825.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| Category: Cardiology | ||||||
| 12/16/2024 | Medtronic, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| 11/26/2024 | CORDIS US CORP. | Cardio (Device) | Food and Beverage | In-kind items and services | $357.92 | General |
| Category: Cardiovascular | ||||||
| 11/22/2024 | CORDIS US CORP. | SELUTION SLRPCTA (Device) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $5,421.25 | Research |
| Study: Research Publication/ Writing Support | ||||||
| 10/27/2024 | Medtronic, Inc. | COREVALVE EVOLUT R (Device) | Food and Beverage | In-kind items and services | $75.57 | General |
| Category: Transcatheter Valve Systems | ||||||
| 10/27/2024 | Recor Medical Inc | PARADISE RENAL DENERVATION SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $11.90 | General |
| Category: Endovascular | ||||||
| 10/04/2024 | Medtronic, Inc. | COREVALVE EVOLUT R (Device) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Transcatheter Valve Systems | ||||||
| 10/04/2024 | Medtronic, Inc. | COREVALVE EVOLUT R (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Transcatheter Valve Systems | ||||||
| 09/19/2024 | Recor Medical Inc | PARADISE RENAL DENERVATION SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Endovascular | ||||||
| 09/17/2024 | CORDIS US CORP. | Cardio (Device) | Food and Beverage | In-kind items and services | $106.72 | General |
| Category: Cardiovascular | ||||||
| 09/16/2024 | IDORSIA PHARMACEUTICALS US INC | Selatogrel | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 09/16/2024 | IDORSIA PHARMACEUTICALS US INC | Selatogrel | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 09/16/2024 | CORDIS US CORP. | Cardio (Device) | Food and Beverage | In-kind items and services | $160.09 | General |
| Category: Cardiovascular | ||||||
| 09/14/2024 | CORDIS US CORP. | Cardio (Device) | Travel and Lodging | Cash or cash equivalent | $680.00 | General |
| Category: Cardiovascular | ||||||
| 09/12/2024 | Medtronic, Inc. | COREVALVE EVOLUT R (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Transcatheter Valve Systems | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,584.00 | General |
| 09/01/2024 | Novartis Pharma AG | LEQVIO (Drug) | — | Cash or cash equivalent | $15.18 | Research |
| Study: CKJX839B12301 & CKJX839B12302 • Category: CARDIOVASCULAR | ||||||
| 08/31/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $12,593.75 | General |
| 08/31/2024 | Novo Nordisk AS | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $807.74 | General |
| 08/31/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $640.69 | General |
| 08/31/2024 | Novartis Pharma AG | LEQVIO (Drug) | — | Cash or cash equivalent | $59.98 | Research |
| Study: CKJX839B12302 • Category: CARDIOVASCULAR | ||||||
| 08/31/2024 | Novartis Pharma AG | LEQVIO (Drug) | — | Cash or cash equivalent | $15.18 | Research |
| Study: CKJX839B12302 • Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $5,421 | 1 |
| ENVISAGE TAVI AF | Daiichi Sankyo Inc. | $2,415 | 3 |
| CKJX839B12302 | Novartis Pharma AG | $75.16 | 2 |
| CKJX839B12301 & CKJX839B12302 | Novartis Pharma AG | $15.18 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 102 | 168 | $40,000 | $9,437 |
| 2022 | 2 | 25 | 50 | $9,740 | $2,085 |
| 2021 | 1 | 11 | 19 | $2,280 | $256.38 |
Total Patients
138
Total Services
237
Medicare Billing
$11,778
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 27 | $15,660 | $4,189 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 35 | $14,350 | $4,015 | 28.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 37 | 80 | $9,600 | $1,015 | 10.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 23 | 26 | $390.00 | $218.40 | 56.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 22 | $6,380 | $1,720 | 27.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 13 | 28 | $3,360 | $364.84 | 10.9% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 11 | 19 | $2,280 | $256.38 | 11.2% |
About Dr. Roxana Mehran, M.D
Dr. Roxana Mehran, M.D is a Cardiovascular Disease healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447203401.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roxana Mehran, M.D has received a total of $568,170 in payments from pharmaceutical and medical device companies, with $136,697 received in 2024. These payments were reported across 318 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($304,841).
As a Medicare-enrolled provider, Mehran has provided services to 138 Medicare beneficiaries, totaling 237 services with total Medicare billing of $11,778. Data is available for 3 years (2021–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location New York, NY
- Active Since 05/18/2006
- Last Updated 07/20/2011
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1447203401
Products in Payments
- GENERAL THERAPIES (Device) $71,188
- Xience V coronary stent system (Device) $36,007
- Savaysa (Drug) $35,592
- Xarelto (Drug) $28,536
- COREVALVE EVOLUT R (Device) $25,988
- Asahi Fielder coronary guide wire (Device) $25,075
- PRALUENT (Drug) $20,307
- LEQVIO (Drug) $10,239
- Cardio (Device) $8,130
- GENERAL THERAPIES (Device) $8,043
- BRILINTA (Drug) $6,664
- Mitra Clip system (Device) $4,936
- Repatha (Biological) $3,900
- SELUTION SLRPCTA (Device) $3,900
- ILARIS (Biological) $3,750
- XARELTO (Drug) $3,421
- WATCHMAN (Device) $3,000
- Indigo System (Device) $2,427
- ENTRESTO (Drug) $2,132
- IVUS Systems (Device) $2,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in New York
Dr. Roger Hajjar, Md, MD
Cardiovascular Disease — Payments: $5.2M
Cardiovascular Disease $5.2M
Dr. Jacob Koruth, M.d, M.D
Cardiovascular Disease — Payments: $3.2M
Cardiovascular Disease $3.2M
Dr. Martin Leon, M.d, M.D
Cardiovascular Disease — Payments: $2.7M
Cardiovascular Disease $2.7M
Dr. Gregg Stone, M.d, M.D
Cardiovascular Disease — Payments: $2.2M
Cardiovascular Disease $2.2M
Adam Rosenbluth, Md, MD
Cardiovascular Disease — Payments: $1.5M
Cardiovascular Disease $1.5M
Dr. Deepak Bhatt, Md, MD
Cardiovascular Disease — Payments: $1.4M
Cardiovascular Disease $1.4M